EU approval for AbbVie Inc.'s next-generation combination therapy Marivet to treat the hepatitis C virus (HCV), announced on the same day the firm reported its second quarter earnings, appears fortuitous as the new drug should offset declining revenues from the company's prior HCV product Viekira Pak and may give the firm another growth-driver alongside booming cancer drug Imbruvica.
AbbVie has a big hole to fill in the immediate future. Its anti-tumor necrosis factor agent Humira (adalimumab) has held...








